NR4A1 and breast cancer: For patients with an intermediate RS, results from the recent prospective Trial Assigning Individualized Options for Treatment (TAILORx) trial [20], which was designed to test whether chemotherapy is beneficial for patients with hormone receptor-positive, HER2 (human epidermal growth factor receptor 2)-negative, node-negative BC who had a mid-range 21-gene RS (11–25, new intermediate score), revealed that adjuvant endocrine therapy alone was non-inferior to chemo-endocrine therapy in the analysis of invasive disease-free survival (IDFS).